| Literature DB >> 29651245 |
Lihua Zuo1,2, Lin Zhou1,2, Tanye Xu1,2, Zhuolun Li1,2, Liwei Liu1,2, Yingying Shi1,2, Jian Kang1,2, Guanmin Gao3, Shuzhang Du1,2, Zhi Sun1,2, Xiaojian Zhang1,2.
Abstract
Xuebijing (XBJ) injection is an ethnomedicinal formula that has been widely used in the therapy of sepsis in China. However, the underlying theraputic mechanisms remain uninvestigated. In this research, a metabolomic method based on UHPLC-Q-Orbitrap HRMS was applied to make a holistic evaluation of XBJ on septic rats which were induced by the classical cecal ligation and puncture (CLP) operation. The plasma metabolic changes were profiled and evaluated by multivariate analytical (MVA) methods. In the results, a total of 41 differential metabolites were identified between CLP-operated group and sham-operated group, which were mainly involved in amino acid metabolism and lipid metabolism. After pathway analysis, it was finally discovered that the majority of the influenced metabolic pathways caused by sepsis mainly involved in energy metabolism, oxidative stress, and inflammation metabolism. When intervened by XBJ injection, 32 of the 41 disordered metabolites had been adjusted in reverse, which suggested that XBJ could mediate the abnormal metabolic pathways synergistically. In conclusion, the present study systematically investigated the efficacy and its underlying therapeutic mechanisms of XBJ on sepsis, while offering a new insight for the subsequent relevant exploration of other Chinese medicine at the same time.Entities:
Keywords: UHPLC-Q-Orbitrap HRMS; Xuebijing; anti-inflammatory; metabolomics; sepsis
Year: 2018 PMID: 29651245 PMCID: PMC5884946 DOI: 10.3389/fphar.2018.00300
Source DB: PubMed Journal: Front Pharmacol ISSN: 1663-9812 Impact factor: 5.810
Figure 1The concentration level of IL-1β, TNF-α, and IL-6 in different groups.
Figure 2(A) The PCA plot of QC and samples in positive ion mode, (B) The PCA plot of QC and samples in negative ion mode, (C) The scatter distribution plot in the first principal components in positive ion mode, (D) The scatter distribution plot in the first principal components in negative ion mode.
Figure 3(A) The PCA plot of the different groups in positive ion mode, (B) The PCA plot of the different groups in negative ion mode, (C) The OPLS-DA plot of the different groups in positive ion mode, (D) The OPLS-DA plot of the different groups in negative ion mode.
Figure 4(A) The permutations test of the C vs. S group in positive ion mode, (B) The VIP plot of the C vs. S group in positive ion mode, (C) The S-plot of the C vs. S group in positive ion mode, (D) The permutations test of the C vs. S group in negative ion mode, (E) The VIP plot of the C vs. S group in negative ion mode, (F) The S-plot of the C vs. S group in negative ion mode.
Figure 5(A) The volcano plot of the C vs. S group in positive ion mode, (B) The volcano plot of the C vs. S group in negative ion mode.
Different metabolites identified between C group vs. S group and adjusted in X group.
| 1 | 116.071 | Proline | C5H9NO2 | 4.48 | 0.36↓ | 1.72↑ | Proline metabolism | 1.076 |
| 2 | 150.058 | L-Methionine | C5H11NO2S | 2.89 | 0.43↓ | 1.63↑ | Methionine metabolism | −0.039 |
| 3 | 229.154 | Prolylleucine | C11H20N2O3 | 1.14 | 0.37↓ | 3.18↑ | Prolylleucine metabolism | −2.614 |
| 4 | 132.102 | Leucine | C6H13NO2 | 9.52 | 0.37↓ | 1.76↑ | Leucine metabolism | −0.267 |
| 5 | 146.165 | Spermidine | C7H19N3 | 1.69 | 0.36↓ | 1.90↑ | Arginine and proline metabolism | −2.081 |
| 6 | 145.061 | L-Glutamine | C5H10N2O3 | 1.07 | 0.50↓ | 1.63↑ | Glutamate metabolism | 0.905 |
| 7 | 160.037 | 4-Methylene-L-glutamate | C6H9NO4 | 1.49 | 0.20↓ | 3.74↑ | Glutamate metabolism | −0.839 |
| 8 | 586.315 | N-Acetyl-D-glucosaminyldiphosphodolichol | C23H43NO12P2 | 1.16 | 0.30↓ | 1.79↑ | N-Glycan biosynthesis | 0.433 |
| 9 | 123.055 | Nicotinamide | C6H6N2O | 1.41 | 0.49↓ | 1.53↑ | Nicotinate and nicotinamide metabolism | 0.736 |
| 10 | 138.055 | Methyl nicotinate | C7H7NO2 | 1.05 | 0.49↓ | 1.86↑ | Nicotinate and nicotinamide metabolism | −0.688 |
| 11 | 581.320 | Stearyl monoglyceridyl citrate | C28H54O12 | 1.63 | 0.41↓ | 1.75↑ | Lipid metabolism | 4.398 |
| 12 | 269.226 | anhydroretinol | C20H28 | 1.27 | 0.49↓ | 0.91 | Vitamin A metabolism | −1.699 |
| 13 | 335.223 | Prostaglandin B1 | C20H32O4 | 1.10 | 0.49↓ | 1.57↑ | Arachidonic acid metabolism | 3.264 |
| 14 | 319.226 | 15-Deoxy-Δ12,14-prostaglandin A1 | C20H30O3 | 1.36 | 0.44↓ | 0.87 | Arachidonic acid metabolism | −2.197 |
| 15 | 218.139 | Propionyl carnitine | C10H19NO4 | 1.07 | 2.05↑ | 0.42↓ | Fatty acid metabolism | −0.755 |
| 16 | 400.342 | Palmitoyl carnitine | C23H45NO4 | 1.36 | 2.03↑ | 0.77 | Fatty acid metabolism | −1.387 |
| 17 | 428.373 | Stearoyl carnitine | C25H49NO4 | 1.02 | 2.77↑ | 0.65↓ | Fatty acid metabolism | −2.557 |
| 18 | 357.278 | Tetracosahexaenoic acid | C24H36O2 | 1.79 | 2.39↑ | 0.86 | Polyunsaturated fatty acid metabolism | −3.490 |
| 19 | 101.023 | 2-oxobutanoic acid | C4H6O3 | 1.02 | 0.50↓ | 1.30 | Propanoate, Cysteine and methionine metabolism | 0.885 |
| 20 | 103.039 | 3-hydroxybutanoic acid | C4H8O3 | 4.33 | 2.46↑ | 0.48↓ | Butanoate metabolism | −2.141 |
| 21 | 124.006 | Taurine | C2H7NO3S | 1.02 | 0.49↓ | 1.55↑ | Taurine and hypotaturine metabolism | 0.240 |
| 22 | 391.283 | 12-Ketodeoxycholic acid | C24H38O4 | 1.14 | 2.15↑ | 0.64↓ | Primary bile acid biosynthesis | −2.214 |
| 23 | 407.280 | Cholic acid | C24H40O5 | 3.70 | 3.84↑ | 0.65↓ | Primary bile acid biosynthesis | 1.889 |
| 24 | 212.002 | 3-Indoxyl sulfate | C8H7NO4S | 1.72 | 0.47↓ | 1.45 | Tryptophan metabolism | 1.581 |
| 25 | 583.336 | Cholic acid glucuronide | C30H48O11 | 1.31 | 0.47↓ | 2.09↑ | Pentose and glucuronate interconversions | 1.974 |
| 26 | 105.110 | Choline | C5H14NO | 1.14 | 2.10↑ | 0.51↓ | Glycerophospholipid metabolism | −4.379 |
| 27 | 476.278 | LysoPE(18:2) | C23H44NO7P | 1.03 | 0.48↓ | 1.56↑ | Phospholipid metabolism | 1.710 |
| 28 | 482.324 | LysoPE(18:0) | C23H48NO7P | 1.17 | 0.49↓ | 1.63↑ | Phospholipid metabolism | −1.111 |
| 29 | 526.315 | LysoPE(22:5) | C27H46NO7P | 1.00 | 0.50↓ | 1.05 | Phospholipid metabolism | 1.452 |
| 30 | 520.339 | LysoPC(18:2) | C26H50NO7P | 7.04 | 0.46↓ | 1.29 | Phospholipid metabolism | −0.914 |
| 31 | 542.321 | LysoPC(20:5) | C28H48NO7P | 1.29 | 0.30↓ | 1.83↑ | Phospholipid metabolism | −3.671 |
| 32 | 546.352 | LysoPC(20:3) | C28H52NO7P | 1.66 | 0.43↓ | 1.95↑ | Phospholipid metabolism | −1.804 |
| 33 | 550.385 | LysoPC(20:1) | C28H56NO7P | 1.04 | 0.47↓ | 1.35 | Phospholipid metabolism | −1.773 |
| 34 | 568.338 | LysoPC(22:6) | C30H50NO7P | 3.21 | 0.49↓ | 1.93↑ | Phospholipid metabolism | −1.576 |
| 35 | 494.323 | LysoPC(16:1) | C24H48NO7P | 1.18 | 0.46↓ | 2.36↑ | Phospholipid metabolism | −2.257 |
| 36 | 510.355 | LysoPC(17:0) | C25H52NO7P | 1.08 | 0.50↓ | 1.59↓ | Phospholipid metabolism | −2.284 |
| 37 | 330.336 | Dihydroceramide | C19H39NO3 | 1.57 | 0.49↓ | 1.65↑ | Sphingolipid metabolism | −4.089 |
| 38 | 352.290 | Sphingosine 1-phosphate | C16H34NO5P | 1.01 | 0.50↓ | 1.57↑ | Sphingolipid metabolism | −4.917 |
| 39 | 703.574 | Palmitoyl sphingomyelin | C39H79N2O6P | 3.27 | 2.07↑ | 0.58↓ | Sphingolipid metabolism | −2.119 |
| 40 | 112.051 | cytosine | C4H5N3O | 1.10 | 0.49↓ | 1.50↑ | pyrimidine metabolism | 0.014 |
| 41 | 179.055 | D-(+)-Glucose | C6H12O6 | 1.89 | 0.47↓ | 1.81↑ | glucose metabolism | 1.762 |
The values have statistical significance (P < 0.05); ↑ The metabolites were up-regulated; ↓ The metabolites were down-regulated.
Figure 6(A) The heat map of the disordered metabolites in C vs. S group, (B) The heat map of the metabolites adjusted by XBJ injection in C, S, and X group.
Figure 7The pathway analysis of the identified metabolites.
Figure 8Disturbed metabolic pathway network in sepsis and the interventional effects of Xuebijing injection. The names marked in red represent up-regulated metabolites in septic rats, and the names marked in blue represent down-regulated metabolites in septic rats. The names marked in black represent undetected metabolites. The metabolites reversed by Xuebijing injection are marked with up and down arrows.